[Flow cytometric 3-color analysis of circulating activated platelets and its clinical significance in ischemic cerebrovascular diseases].
OBJECTIVE
To explore the flow cytometric 3-color analysis of circulating activated platelets (CAP) and its clinical significance in ischemic cerebrovascular diseases.


METHODS
The fibrinogen receptor (FIB-R) and P-selectin (CD62P) were used for molecular marker of CAP, which were analyzed by flow cytometric 3-color immunofluorescence.


RESULTS
Expression of FIB-R and CD62P on the resting platelet membrane surface was very lower in normal individuals, the median of FIB-R and CD62P positive percent was 1.40% and 0.70% respectively. Platelet can be obviously activated by 0.1 micromol/L ADP, and 10.0 micromol/L ADP leaded to the peak expression of FIB-R and CD62P on the activated platelet membrane surface, FIB-R and CD62P positive percent of 87.8% and 81.34% respectively. That monoclonal antibody of the FIB-R combined with ADP activating platelets was inhibited by synthetic peptide (RGDS). The quantity of CAP with FIB-R expression was markedly higher (P < 0.01) and the amount of CAP with CD62P expression was not significantly higher (P > 0.05) in blood of 112 patients with thrombotic tendency and 120 patients with ischemic cerebrovascular diseases than in healthy individuals. The expression of CAP with FIB-R of in front and behind treatment of acute cerebral infarction continuously decreased (P < 0.05), and the quantity of CAP with FIB-R expression was related negatively to Europe stroke score (ESS) of patients with acute cerebral infarction.


CONCLUSIONS
The FIB-R may be regarded as sensitive and specific molecular marker in detection of CAP. The level of platelet activation in vivo can be reflected accurately by flow cytometric 3-color analysis of CAP, which has an important clinical significance for the study of pathogenesis, estimation of prognosis and supervision of curative effect in ischemic cerebrovascular diseases.
Wang
J
J
The First Hospital, Beijing Medical University, Beijing 100034, China.
Cao
L
L
He
M
M
D000244:Adenosine Diphosphate / Q000494:pharmacology; D000368:Aged; D001792:Blood Platelets / Q000187:drug effects / Q000378:metabolism; D002545:Brain Ischemia / Q000097:blood*; D004305:Dose-Response Relationship, Drug; D005260:Female; D005434:Flow Cytometry / Q000379:methods*; D006801:Humans; D008297:Male; D008875:Middle Aged; D019007:P-Selectin / Q000097:blood; D015539:Platelet Activation / Q000502:physiology*; D019039:Platelet Glycoprotein GPIIb-IIIa Complex / Q000378:metabolism
D019007:P-Selectin; D019039:Platelet Glycoprotein GPIIb-IIIa Complex; D000244:Adenosine Diphosphate